Search

Your search keyword '"Narita, Yoshitaka"' showing total 373 results

Search Constraints

Start Over You searched for: Author "Narita, Yoshitaka" Remove constraint Author: "Narita, Yoshitaka" Database Unpaywall Remove constraint Database: Unpaywall
373 results on '"Narita, Yoshitaka"'

Search Results

1. Pediatric atypical teratoid/rhabdoid tumor in the cauda equina with rapid tumor progression: A case report and review of the literature

3. Boron neutron capture therapy prolongs survival in a patient with a recurrent malignant peripheral nerve sheath tumor—A case report

4. Early progressive disease in IDH-mutant grade 2 and 3 astrocytoma without CDKN2A/B homozygous deletions may indicate radiation necrosis

5. Identification of barriers to implementation of precision oncology in patients with rare cancers

6. The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma

7. Development of a rapid and comprehensive genomic profiling test supporting diagnosis and research for gliomas

8. 10206-GGE-21 MOLECULAR LANDSCAPE AND TUMOR EVOLUTION IN ASTROBLASTOMA

9. 10007-ACT-2 FIRST IN HUMAN STUDY OF DSP-0390, AN ORAL EMOPAMIL BINDING PROTEIN (EBP) INHIBITOR, IN RECURRENT HIGH-GRADE GLIOMA (HGG): PRELIMINARY RESULTS

10. 10064-GGE-6 A MULTI-OMIC LANDSCAPE OF GLIOBLASTOMA, IDH-WILD TYPE

11. 10082-RT-1 LONG-TERM RESULTS OF A BNCT PHASE II CLINICAL TRIAL USING AN ACCELERATOR-BASED NEUTRON SOURCE FOR PATIENTS WITH RECURRENT GLIOBLASTOMA

15. 10024-CO-1 A MULTICENTER PERFORMANCE COMPARISON STUDY OF AN IDH STATUS PREDICTION MODEL USING THE VISUAL TRANSFORMER MODEL

19. CTNI-72. PHASE II TRIAL OF PATHOLOGY-BASED THREE-GROUP TREATMENT STRATIFICATION FOR PATIENTS WITH CNS GERM CELL TUMORS: A LONG-TERM FOLLOW-UP STUDY

21. CTNI-67. FIRST IN HUMAN STUDY OF DSP-0390, AN ORAL EMOPAMIL BINDING PROTEIN (EBP) INHIBITOR, IN RECURRENT HIGH-GRADE GLIOMA (HGG): PRELIMINARY RESULTS

23. EPCO-32. DISSECTING THE INTRA- AND INTER-TUMORAL HETEROGENEITY UNDERLYING GLIOBLASTOMA PATHOGENESIS UTILIZING MULTI-OMICS ANALYSIS

24. Development of a rapid and comprehensive genomic profiling test supporting diagnosis and research for brain tumors

25. Karnofsky Performance Status and Quality of Life in Patients with Relapsed or Refractory Primary CNS Lymphoma from a Phase I/II Study of Tirabrutinib

26. Consulting a neurosurgeon upon initial medical assessment reduces the time to the first surgery and potentially contributes to improved prognosis for glioblastoma patients

27. Recommended first-line management of asymptomatic brain metastases from EGFR mutant and ALK positive non-small cell lung cancer varies significantly according to specialty: an international survey of clinical practice

30. Abstract 1506: Decoding multi-omics genetic profiling reveals heterogeneity in adult pan-gliomas

31. Supplementary Figures and Legends from Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma

32. Supplementary Figures and Legends from Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma

33. Supplementary Tables from Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma

34. Data from Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma

35. Data from Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma

36. Supplementary Tables from Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma

37. Supplementary Figure S2 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

38. Supplementary Table S12 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

39. Supplementary Figure S4 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

40. Supplementary Data from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

41. Supplementary Figure S4 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

42. Supplementary Figure S1 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

43. Supplementary Figure S2 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

44. Supplementary Figure S3 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

45. Supplementary Data from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

46. Supplementary Figure S3 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

47. Supplementary Figure S1 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

48. Supplementary Table S12 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

49. Supplementary Figures SF1-SF8 from Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas

50. Supplementary Table from Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas

Catalog

Books, media, physical & digital resources